Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host

Manuel Albanese\textsuperscript{1,2,3,4}†, Takanobu Tagawa\textsuperscript{3,4,5}† and Wolfgang Hammerschmidt\textsuperscript{3,4}*

\textsuperscript{1}Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, Ludwig Maximilian University of Munich, Munich, Germany, \textsuperscript{2}Istituto Nazionale di Genetica Molecolare, “Romeo ed Enrica Invernizzi,” Milan, Italy, \textsuperscript{3}Research Unit Gene Vectors, EBV Vaccine Development Unit, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany, \textsuperscript{4}German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany, \textsuperscript{5}HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States

Epstein-Barr virus (EBV) is a double-stranded DNA virus of the Herpesviridae family. This virus preferentially infects human primary B cells and persists in the human B cell compartment for a lifetime. Latent EBV infection can lead to the development of different types of lymphomas as well as carcinomas such as nasopharyngeal and gastric carcinoma in immunocompetent and immunocompromised patients. The early phase of viral infection is crucial for EBV to establish latency, but different viral components are sensed by cellular sensors called pattern recognition receptors (PRRs) as the first line of host defense. The efficacy of innate immunity, in particular the interferon-mediated response, is critical to control viral infection initially and to trigger a broad spectrum of specific adaptive immune responses against EBV later. Despite these restrictions, the virus has developed various strategies to evade the immune reaction of its host and to establish its lifelong latency. In its different phases of infection, EBV expresses up to 44 different viral miRNAs. Some act as viral immunoevasins because they have been shown to counteract innate as well as adaptive immune responses. Similarly, certain virally encoded proteins also control antiviral immunity. In this review, we discuss how the virus governs innate immune responses of its host and exploits them to its advantage.

KEYWORDS
herpesvirus, interferon, microRNA, immune evasion, natural killer cell, antiviral response, T cell, B cell

Introduction

Epstein-Barr virus (EBV), also referred to as human herpesvirus 4 (HHV-4) is a virus of the Gammaherpesvirinae subfamily with an encapsidated, linear, double-stranded DNA genome of approximately 160 kbs and an envelope of about 180 nm in diameter. More than 95% of the adult population worldwide is infected. Primary infection occurs...
mainly via saliva and is often asymptomatic in childhood, but is frequently associated with Infectious Mononucleosis (IM), if the first contact is delayed until adolescence or adulthood. IM patients have a higher risk of developing Multiple Sclerosis or malignant diseases later in life (Crawford, 2001; Ascherio and Munger, 2015). After infection, the virus establishes latency in mature B cells and persists in long-lived memory B cells. EBV is associated with certain B cell malignancies such as Hodgkin lymphoma, Burkitt’s lymphoma, and post-transplant lymphoproliferative disorder (PTLD) but the virus also causes nasopharyngeal carcinoma and gastric carcinoma in epithelial cells, which EBV can also infect. In immunocompromised individuals, EBV causes PTLD and the majority of acquired immunodeficiency syndrome (AIDS)-defining non-Hodgkin’s lymphoma (Yarchoan and Uldrick, 2018). EBV is a critical human tumor virus and a class 1 carcinogen (International Agency for Research on Cancer [IARC], 1997).

Epstein-Barr virus supports its lifelong persistence in us by minimizing the expression of viral proteins to limit viral detection and to escape from antiviral immunity. During EBV's life cycle, three different latent phases are characterized by distinct viral gene expression profiles: latency 0/1 (no viral proteins or only EBV nuclear antigen 1 (EBNA1)); latency III (all latent viral proteins (6 EBNA, 3 latent member proteins; LMPs)); and latency II (a subset of latent viral proteins). During latency, up to 44 microRNAs (miRNAs) and two non-coding RNAs (EBERs) are also expressed. In in vitro infected human B cells, various lytic viral genes are expressed initially together with latent EBV genes in the so-called pre-latent phase of infection (Kalla et al., 2010; Kalla and Hammerschmidt, 2012), but lytic gene expression ceases when the incoming EBV DNA becomes epigenetically repressed within a few days.

During latent infection in resting cells, several copies of the EBV genome are stably maintained as fully chromatinized extrachromosomal plasmids which, in proliferating cells, replicate in synchrony with host cell DNA. To allow virus to spread to neighboring cells, reactivation occurs in B cells when they encounter their cognate antigen in vivo (Laichalk and Thorley-Lawson, 2005), but sporadic entry into EBV’s productive, lytic phase also occurs spontaneously in latently EBV infected cell lines in vitro. Lytic reactivation is initiated by the viral protein BZLF1, a member of the activator protein 1 (AP-1) family of transcription factors, which induces a massive synthesis of all viral proteins needed for the assembly and egress of virions (Buschle and Hammerschmidt, 2020).

The innate immune system is the frontline defense to protect the host from viral infection (Li and Wu, 2021). B cells and epithelial cells that EBV infects but also monocytes-derived macrophages (MDMs), dendritic cells (DCs), and plasmacytoid dendritic cells (pDCs) can sense virion components. These immune cells express a plethora of pattern recognition receptors, PRRs. Different PRRs recognize different viral components: Toll-like receptor 2 (TLR2) senses the viral dUTPase in monocytes (Gaudreault et al., 2007; Ariza et al., 2009); in monocytes and pDCs and TLR9 senses the unmethylated CpG motifs of virion DNA (Fiola et al., 2010; Bouvet et al., 2021). The EBERs are recognized by TLR3, TLR7, and Retinoic acid-inducible gene I (RIG-I) in different types of established cell lines (Samanta et al., 2006; Ikawri et al., 2009; Li et al., 2019) but not when EBV infects primary B cells (Bouvet et al., 2021), which is an unexpected finding. EBV is sensed by interferon gamma inducible protein 16 (IFN16) (Ansari et al., 2013) in epithelial cells in which EBV induces TRIM29, a negative regulator of STING (Xing et al., 2017) (stimulator of interferon genes) and an adaptor protein of cytosolic DNA sensors. A STING inhibitor suppressed B cell transformation by EBV (Miyagi et al., 2021) although B cells barely express STING (Mrozek-Gorska et al., 2019). Further research is needed to clarify its role in EBV infection.

Despite the known innate immune responses EBV establishes long-term latency in most of us, suggesting that it has evolved to escape from human immune recognition. EBV uses several viral gene products with immune evasive functions in different phases of the viral life cycle since many viral components are antigens and are recognized by the host. We summarize recent advancements in understanding the diverse classes of molecules that EBV uses to evade innate immune responses.

**BPLF1**

BPLF1 is a large (3149 aa) EBV protein expressed during EBV’s lytic phase and contained in the tegument of virions. BPLF1 stabilizes RAD18 ubiquitin complexes and acts as a deubiquitylase (removing the ubiquitin-like protein NEDD8) important for lytic viral DNA replication and production of infectious virions (Gastaldello et al., 2010; Kumar et al., 2014). Infection of humanized mice with a BPLF1-knockout virus showed reduced infectivity and delayed B cell transformation suggesting that BPLF1 contributes to but is not essential for the virus to spread in vivo (Whitehurst et al., 2015). The N-terminal region of the protein contains a deubiquitinating (DUB) domain, which interacts with proliferating cell nuclear antigen (PCNA) to reduce the cellular DNA damage response after lytic reactivation (Whitehurst et al., 2012). The DUB domain also reduces immune recognition during lytic activation by removing polyubiquitin chains from various components of TLR signaling, including NEMO, IKKα, and TRAF6 (Saito et al., 2013; van Gent et al., 2014). BPLF1 was further reported to interact with the 14-3-3 protein and the E3 ligase tripartite motif-containing protein 25 (TRIM25) mitigating type I interferon (IFN)–mediated responses by sequestering TRIM25 into a trimeric complex. Since RIG-I’s functions depend on ubiquitination by TRIM25, its inhibition causes the loss of the ubiquitin scaffold on RIG-I and affects successive
downstream signaling cascades (Gupta et al., 2019). The decreased NF-κB activation in response to EBV reactivation reduces pro-inflammatory cytokine secretion levels. BPLF1 may also have an immune suppressive role immediately after B cell infection since BPLF1 contained in EBV’s infectious particles can control TLR signaling (van Gent et al., 2014) and BPLF1 is also transiently expressed during EBV’s pre-latent phase (Mrozek-Gorska et al., 2019).

EBV nuclear antigen 1

EBV nuclear antigen 1 is a homo-dimeric protein expressed in all types of viral latency and latency 0. EBNA1 has crucial functions to maintain EBV genomes stably, to replicate viral DNA, and to partition the newly replicated EBV genomes to daughter cells. EBNA1 binds to the EBV origin of plasmid replication (oriP), which is critical for maintaining and replicating the viral genome and for its partitioning during mitosis (Chiu and Sugden, 2018). EBNA1’s amineterminus binds cellular chromatin to localize EBV genomes to perichromatin and contains a glycine alanine repeat (GAr) domain with immune evasive function reducing presentation of EBNA1 epitopes to CD8+ cytotoxic T cells (Blake et al., 1997; Yin et al., 2003).

EBNA1’s role in regulating innate immunity is less clear. It interferes with functional NF-κB activation in different carcinoma cell lines (Valentine et al., 2010) and it can contribute to the development of EBV-associated tumors and their progression by activating AP-1 and signal transducer and activator of transcription 1 (STAT1) (O’Neil et al., 2008) and inhibiting TGF-β1 (Wood et al., 2007; Flavell et al., 2008). This is counterintuitive because STAT1 activation typically induces strong anti-viral IFN responses. EBV suppresses these “adverse effects” together with other immunosuppressants such as EBNA2 or viral miRNAs. EBNA1 also induces CXCL12 secretion to recruit regulatory T cells and to create an immunosuppressive microenvironment (Huo et al., 2020). Finally, EBNA1 also regulates the expression of NKG2D ligands which reduces the recognition of EBV infected cells by NK cells shortly after infection (Westhoff Smith et al., 2021).

EBNA2

EBNA2 acts as the main transcriptional transactivator (Kempkes and Ling, 2015) and is essential for the reprogramming and transformation of primary B cells infected by EBV in vitro (Hammerschmidt and Sugden, 1989). EBNA2 induces a plethora of cellular genes including MYC (Kaiser et al., 1999) and genes coding for cell surface and adhesion molecules such as CD21 and CD23, but EBNA2 also activates multiple viral proteins including EBNA1, LMP1, and LMP2 (Kempkes and Ling, 2015). Regarding EBNA2’s role in innate immunity, it induces the expression of the IL-18 receptor (IL-18R) in primary B cells (Pagès et al., 2005). IL-18R may function differently depending on its ligands, the pro-inflammatory and anti-inflammatory cytokines IL-18 and IL-37, respectively. With IL-37, IL-18R can inhibit innate immune responses in general (Nold-Petry et al., 2015) but the contribution of the IL-18R pathway to EBV’s strategy of immune evasion needs to be assessed. EBNA2 was also shown to upregulate TNF-α and LT-α to support cell proliferation (Spender et al., 2001). EBNA2 also regulates host miRNAs hsa-miR-21 and miR-146a that act as negative feedback of type I IFN responses in the RIG-I pathway (Rosato et al., 2012). Already in the 1990s, EBNA2 was described to render the infected cells insensitive to IFN (Aman and von Gabain, 1990) and to suppress interferon stimulated genes (ISGs) but EBNA2 also induces low levels of IFN-β suggesting that chronic low levels of IFN may desensitize cells and dampen proper anti-viral responses (Kanda et al., 1992, 1999). In 293T and HeLa cells, EBNA2 activates STAT3, which could provide a growth advantage to EBV infected cells (Muromoto et al., 2009).

BCRF1 (vIL-10)

Epstein-Barr virus also manipulates innate immunity using viral IL-10 (vIL-10) encoded by the BCRF1 gene of EBV, a viral homolog of human IL-10 (Sin and Dittmer, 2012). vIL-10 is an anti-inflammatory cytokine that suppresses secretion of pro-inflammatory cytokines such as IFN-γ and IL-2 from EBV infected PBMCs (Jochum et al., 2012a). NK cells can sense and lyse EBV infected cells particularly during EBV’s lytic phase. CD4+ T cells can enhance NK cell activity, but vIL-10 suppresses this adjuvant T cell effect reducing the cytotoxic activity of NK cells (Jochum et al., 2012a). vIL-10 also controls adaptive immunity by suppressing TAP1, class I HLA, and co-stimulatory molecules such as ICAM-1 (Zeilidier et al., 1997; Salek-Ardakani et al., 2002). Unlike hIL-10, vIL-10 does not induce class II MHC (Go et al., 1990) or promotes thymocyte proliferation (MacNeil et al., 1990) probably due to its lower receptor affinity compared to hIL-10 (Liu et al., 1997). In a recent study, vIL-10 reduced phosphorylation of STAT3 and vIL-10-treated monocytes showed weaker phagocytosis of apoptotic cells compared to hIL-10-treated cells (Jochum et al., 2012a). vIL-10 also controls adaptive immunity by suppressing TAP1, class I HLA, and co-stimulatory molecules such as ICAM-1 (Zeilidier et al., 1997; Salek-Ardakani et al., 2002). Unlike hIL-10, vIL-10 does not induce class II MHC (Go et al., 1990) or promotes thymocyte proliferation (MacNeil et al., 1990) probably due to its lower receptor affinity compared to hIL-10 (Liu et al., 1997). In a recent study, vIL-10 reduced phosphorylation of STAT3 and vIL-10-treated monocytes showed weaker phagocytosis of apoptotic cells compared to hIL-10-treated cells (Jochum et al., 2012a). vIL-10 also controls adaptive immunity by suppressing TAP1, class I HLA, and co-stimulatory molecules such as ICAM-1 (Zeilidier et al., 1997; Salek-Ardakani et al., 2002). Unlike hIL-10, vIL-10 does not induce class II MHC (Go et al., 1990) or promotes thymocyte proliferation (MacNeil et al., 1990) probably due to its lower receptor affinity compared to hIL-10 (Liu et al., 1997). In a recent study, vIL-10 reduced phosphorylation of STAT3 and vIL-10-treated monocytes showed weaker phagocytosis of apoptotic cells compared to hIL-10-treated cells (Jochum et al., 2012a). vIL-10 also controls adaptive immunity by suppressing TAP1, class I HLA, and co-stimulatory molecules such as ICAM-1 (Zeilidier et al., 1997; Salek-Ardakani et al., 2002). Unlike hIL-10, vIL-10 does not induce class II MHC (Go et al., 1990) or promotes thymocyte proliferation (MacNeil et al., 1990) probably due to its lower receptor affinity compared to hIL-10 (Liu et al., 1997).
EBV infected cells release type I and II interferons leading to non-canonical NF-κB activation of the JAK/STAT pathway as well as both canonical and IFN-γ-induced signaling (Zhang L. et al., 2004; Huye et al., 2007; Ning et al., 2008) and interferon regulatory factor 7 (IRF7) via TRAF6 and RIP mediated ubiquitination (Zhang et al., 2001). LMP1 drives an innate anti-viral response but it also evokes an anti-viral state in infected cells. LMP1 induces interferon regulatory factor 7 (IRF7) upon encounter with viral DNA and its detection by TLR9 in plasmacytoid dendritic cells (pDCs) released high levels of type II interferon responses in epithelial cells (Shah et al., 2009). Interestingly, LMP2B was also found to contribute to IFN receptor degradation, suggesting that the N-terminal cytosolic tail of LMP2A, which LMP2B lacks, is not important for this ubiquitin-dependent mechanism (Shah et al., 2009).

**Latent membrane protein 1**

Latent membrane protein 1 contains 6 transmembrane domains and a C-terminal signaling domain and is located mainly in intracellular membranes (Lam and Sugden, 2003). LMP1 mimics a constitutive, i.e., ligand-independent CD40 receptor and its downstream signaling cascade (Kilger et al., 1998; Kieser and Sterz, 2015) contributing to survival and proliferation of EBV infected B cells (Wang et al., 1985; Zimmer-Strobl et al., 1996; Kilger et al., 1998). LMP1 drives an innate anti-viral response but it also evokes an anti-viral state in infected cells. LMP1 induces interferon regulatory factor 7 (IRF7) via TRAF6 and RIP mediated ubiquitination (Zhang and Pagano, 2000; Huye et al., 2007; Ning et al., 2008) and activates the JAK/STAT pathway as well as both canonical and non-canonical NF-κB signaling pathways (Gires et al., 1999; Zhang L. et al., 2004; Huye et al., 2007). As a consequence, EBV infected cells release type I and II interferons leading to an upregulation of ISGs including ISG15, STAT1, and 2′,5′-oligoadenylate synthetase (OAS) (Richardson et al., 2003; Zhang J. et al., 2004; Najjar et al., 2005). Using LMP1 mutants, STAT1 regulation was shown to depend on both signaling domains of LMP1, CTAR1, and CTAR2 (Zhang L. et al., 2004). The authors suggested that this anti-viral response can be advantageous for the virus because it also supported latent infection in their experimental model (Zhang J. et al., 2004; Zhang L. et al., 2004). Of note, most of these reports rely on latently EBV infected, established B cell lines.

Recent reports identified additional immune evasive functions of LMP1. LMP1 downregulated TLR9 and reduced the recognition of non-CpG methylated viral DNA (Fathallah et al., 2010). Later, newly EBV infected B cells were found to be rather inert to sensing viral DNA (Bouvet et al., 2021), but plasmacytoid dendritic cells (pDCs) released high levels of type I IFN upon encounter with viral DNA and its detection by TLR9 (Bouvet et al., 2021). In 293T cells, LMP1 expression promoted RIG-I degradation (Xu et al., 2018), which might also dampen antiviral responses.

**Latent membrane protein 2**

The viral LMP2 gene encodes two proteins, LMP2A and LMP2B, which differ in their N-terminal domains. Both LMP2A and LMP2B are integral transmembrane proteins embedded in the plasma membrane with their 12 transmembrane spanning domains. LMP2A's N-terminal domain is cytosolic and contains two proline-rich PY domains as well as an immunoreceptor tyrosine-based activation motif (ITAM). The ITAM motif interacts with signal mediators of the B-cell receptor (BCR), mimics an active BCR (Engels et al., 2001a,b) and maintains a “tonic” B cell receptor-like signal (Mancao et al., 2005) and functions of LMP1. LMP1 downregulated interferon mediated responses affecting ISG-driven transcription (Bouvet et al., 2021).

Epstein-Barr virus encodes 44 mature miRNAs which are important for cell survival and proliferation in the pre-latent phase of B cell infection (Seto et al., 2010; Feederle et al., 2011). Recently, many viral miRNAs were also found to govern innate and adaptive immune responses in vitro (Albanese et al., 2016; Tagawa et al., 2016; Bouvet et al., 2021) and in humanized mice in vivo (Muram et al., 2019). miRNAs regulate important proteins in different pathways of innate immunity. EBV miR-BART15 targets the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome and EBV mir-BHRF1-2 was shown to regulate the IL-1 receptor preventing IL-1β release and downstream activation (Haneklaus et al., 2012; Skinner et al., 2017). EBV miR-BART2 targets MICB facilitating immune escape from Natural Killer (NK) cells (Nachmani et al., 2009). EBV miRNAs in primary B cells target key components of the interferon pathway reducing production and release of IFN from infected cells as well as autocrine and paracrine IFN mediated responses affecting ISG-driven transcription (Bouvet et al., 2021). Additional targets involved...
### TABLE 1 Overview of cellular functions regulated by EBV proteins and miRNAs.

| Target          | Function                  | Viral regulator                  | References                              |
|-----------------|---------------------------|----------------------------------|-----------------------------------------|
| TLR2            | Extracellular PRR         | BGLF5,                            | van Gent et al., 2015                   |
| TLR9            | Endosomal PRR             | LMP1, BGLF5, BGLF5                | Futhallah et al., 2010; van Gent et al., 2011 |
| RIG-I            | Cytosolic PRR             | miR-BART6 and miR-BART19, LMP1, miR-BART3, BRLF1 | Bouvet et al., 2021; Xu et al., 2018; Lu et al., 2017; Long et al., 2021 |
| NLRP3           | Cytosolic PRR             | miR-BART15                        | Haneklaus et al., 2012                  |
| TRIM25          | Adapter (Ubiquitin ligase)| BPLF1                             | Gupta et al., 2019                      |
| TRAF6           | Adapter (Ubiquitin ligase)| BPLF1, LMP1                       | Saito et al., 2013; van Gent et al., 2014; Haye et al., 2007; Ning et al., 2008; Zhang and Pagano, 2000 |
| IRAK2           | Protein kinase            | miR-BART22                        | Bouvet et al., 2021                     |
| NEMO            | Protein kinase            | BPLF1                             | van Gent et al., 2014                   |
| IKKα            | Protein kinase            | BPLF1                             | van Gent et al., 2014                   |
| IKKβ            | Protein kinase            | miR-BART17                        | Bouvet et al., 2021                     |
| NF-kB           | Transcription factor      | EBNA1                             | Valentine et al., 2010                  |
| IRF3            | Transcription factor      | BRLF1, BGLF4, BHRF1, BFRF1,        | Bentz et al., 2010; Wang et al., 2009; Vilmorin et al., 2021; Wang et al., 2020 |
| IRF7            | Transcription factor      | BZLF1, BRLF1, BILF4 (LF2)         | Hahn et al., 2005; Bentz et al., 2010; Wu et al., 2009 |
| IFN pathway     |                           |                                   |                                         |
| IFNAR1          | Extracellular receptor    | LMP2                              | Shah et al., 2009                       |
| IFNAR2          | Extracellular receptor    | LMP2                              | Shah et al., 2009                       |
| JAK1            | Protein kinase            | miR-BART3                         | Bouvet et al., 2021                     |
| JAK2            | Protein kinase            | miR-BART2                         | Bouvet et al., 2021                     |
| TYK2            | Protein kinase            | BGLF2                             | Liu et al., 2020                        |
| STAT1           | Transcription factor      | EBNA1                             | O’Neil et al., 2008; Wood et al., 2007  |
| STAT2           | Transcription factor      | BGLF2                             | Jangra et al., 2021                     |
| STAT3           | Transcription factor      | EBNA2, BCRF1 (vIL-10)             | Muromoto et al., 2009; Jog et al., 2018 |
| IRF9            | Transcription factor      | miR-BART1                         | Bouvet et al., 2021                     |
| Cytokines       |                           |                                   |                                         |
| IL-6            | Cytokine                  | LMP2                              | Stewart et al., 2004                    |
| M-CSF           | Cytokine                  | BARF1                             | Hoebe et al., 2012                      |
| TGFβ1           | Cytokine                  | EBNA1                             | Flavell et al., 2008; Wood et al., 2007; Huo et al., 2020 |
| IFN-γ           | Cytokine                  | BCRF1 (vIL-10)                    | Jochum et al., 2012a                    |
| IL-2            | Cytokine                  | BCRF1 (vIL-10)                    | Jochum et al., 2012a                    |
| TNF-α           | Cytokine                  | EBNA2                             | Spender et al., 2001                    |
| LT-α            | Cytokine                  | EBNA2                             | Spender et al., 2001                    |
| IFN-β           | Cytokine                  | EBNA2                             | Kanda et al., 1992; Kanda et al., 1999  |
| IL-1R           | Receptor                  | miR-BHRF1-2                       | Skinner et al., 2017                   |
| TRAF2           | Signal transducer         | LMP2                              | Guasparri et al., 2008                  |
| Gene regulation |                           |                                   |                                         |
| CBP             | Transcription factor      | miR-BART16                        | Hooykaas et al., 2017                   |
| PCNA            | Replication factor        | BPLF1                             | Whitehurst et al., 2015; Whitehurst et al., 2012 |
| hsa-miR-21      | microRNA                  | EBNA2                             | Rosato et al., 2012                     |
| hsa-miR-146a    | microRNA                  | EBNA2                             | Rosato et al., 2012                     |
| NK cell function|                           |                                   |                                         |
| NKG2D           | Activating receptor       | EBNA1                             | Westhoff Smith et al., 2021            |
| MICB            | Receptor                  | miR-BART-2                        | Nachmani et al., 2009                   |
Epstein-Barr virus lytic proteins

In latently infected cells certain viral genes can control innate immunity, but lytic genes also undermine immune functions. IRF7 was shown to be regulated by the immediate early genes BZLF1 (Hahn et al., 2005) and BRLF1 (Bentz et al., 2010). Similarly, several lytic proteins, BGLF4 (Wang et al., 2009), BRLF1 (Bentz et al., 2010), BHRF1 (Vilmunen et al., 2021), and BFRF1 (Wang et al., 2020) target IRF3. It and IRF7 are critical for type I IFN production and downstream ISG signaling, suggesting that the orchestrated suppression of both IRF3 and IRF7 is important in EBV’s lytic, productive phase. BGLF2 was identified to control all three types of IFN (α, β, ε) as it interferes with STAT1/STAT2 (Jangra et al., 2021) and tyrosine kinase 2 (TYK2) functions (Liu et al., 2020). viral lytic genes also target PRRs. The BGLF5 exonuclease downregulates TLR2 (van Gent et al., 2015) and the dsDNA sensor TLR9 (van Gent et al., 2011). BRLF1 not only inhibits IRF3 but also suppresses transcription of RNA polymerase III-dependent immunogenic small RNAs dampening the RIG-I pathway (Long et al., 2021). Secreted BARF1 is a decoy receptor of macrophage colony stimulating factor (M-CSF) interfering with macrophage activation (Hoebbe et al., 2012). Immune evasion appears to be particularly important during latent infection as compared to EBV’s lytic phase, when viral host shut-off mechanisms compromise cellular protein synthesis and thus...
infection will be important to identify potential therapeutic approaches to the virus and its crucial factors that are responsible for successful infection of EBV’s genuine target cells. A better understanding of the importance of candidates for immune evasion in the different phases of EBV infection. Using genetic EBV mutants that differ only in single genes are also supportive. For example, we found that the EBV gene BILF4 (LF2), which was shown to play a role in restricting innate immune response (Wu et al., 2009), did not show any reduction in IFN response in freshly infected B cells (Bouvet et al., 2021). This result suggested that data obtained from phenotypic studies in established cell lines are not necessarily relevant in models recapitulating critical steps in infection of EBV’s genuine target cells. A better understanding of the virus and its crucial factors that are responsible for successful infection will be important to identify potential therapeutic targets to prevent or cure EBV-associated diseases.

Discussion

The data discussed above and summarized in Table 1 and Figure 1 show that EBV has evolved to encode different classes of immune evasins, which contribute to successful infection and stable latency in its human host. Many factors have been found to play various but likely crucial roles in evading innate immunity and probably more factors and new principles will be discovered. Moreover, it appears difficult to assess the importance and contribution of each individual immune evasion detected or claimed in the literature. Few findings have been independently confirmed or falsified. This uncertainty is partly due to the many different experimental systems and models used by different groups working in this field of virology and antiviral immunity.

Use of models that closely mimic in vivo infection is a potential solution to this problem. We recently showed that primary human B cells constitute a valid model to assess the importance of candidates for immune evasion in the different phases of EBV infection. Using genetic EBV mutants that differ only in single genes are also supportive. For example, we found that the EBV gene BILF4 (LF2), which was shown to play a role in restricting innate immune response (Wu et al., 2009), did not show any reduction in IFN response in freshly infected B cells (Bouvet et al., 2021). This result suggested that data obtained from phenotypic studies in established cell lines are not necessarily relevant in models recapitulating critical steps in infection of EBV’s genuine target cells. A better understanding of the virus and its crucial factors that are responsible for successful infection will be important to identify potential therapeutic targets to prevent or cure EBV-associated diseases.

Author contributions

MA, TT, and WH conceptualized the topic. MA and TT researched and analyzed the literature, and drafted the manuscript including interpretations. WH analyzed the background literature, and wrote and finalized the manuscript together with MA and TT. All authors approved the final version of the manuscript, ensured the accuracy and integrity of the work, and agreed to be accountable for all aspects of the work.

Acknowledgments

We thank our colleagues in the EBV community and acknowledge their many publications which have been a valuable source while writing this mini review. We attempted to be as inclusive as we could but for size limitations we could not include all pertinent sources. We also apologize to authors whose contributions we have inadvertently missed.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Albanese, M., Tagawa, T., Bouvet, M., Maliqi, L., Lutter, D., Hoser, J., et al. (2016). Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 113, E6467–E6475. doi: 10.1073/pnas.1605884113

Aman, P., and von Gabain, A. (1990). An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines. EMBO J. 9, 147–152. doi: 10.1002/j.1460-2075.1990.tb08001.x

Ansari, M. A., Singh, V. V., Dutta, S., Veertil, M. V., Dutta, D., Chikoti, L., et al. (2013). Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells. J. Virol. 87, 8606–8623.

Ariza, M. E., Glaser, R., Kaumaya, P. T., Jones, C., and Williams, M. V. (2009). The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 182, 851–859. doi: 10.4049/jimmunol.182.2.851

Ascherio, A., and Munger, K. L. (2015). EBV and autoimmunity. Curr. Top. Microbiol. Immunol. 390, 365–385.

Bentz, G. L., Liu, R., Hahn, A. M., Shackelford, J., and Pagano, J. S. (2010). Epstein-Barr Virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology 402, 121–128. doi: 10.1016/j.virology.2010.03.014

Blake, N., Lee, S., Redchenko, I., Thomas, W., Steven, N., Leese, A., et al. (1997). Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791–802. doi: 10.1016/s1074-7613(00)80397-0

Bouvet, M., Voigt, S., Tagawa, T., Albanese, M., Chen, Y. A., Chen, Y., et al. (2021). Multiple viral microRNAs regulate interferon release and signaling early
during infection with Epstein-Barr virus. mBio 12:e3440. doi: 10.1128/mBio.03440-20

Breitmeier, M., Mautner, J., Laxx, G., and Hammerschmidt, W. (1996). The latency membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J. Gen. Virol. 77, 2807–2818.

Buschle, A., and Hammerschmidt, W. (2020). Epigenetic lifestyle of Epstein-Barr virus. Semin. Immunopathol. 42, 131–142.

Buschle, A., Mrozek-Gorska, P., Cernilova, F.M., Ettinger, A., Pich, D., Krebs, S., et al. (2021). Epstein-Barr virus inactivates the transcription and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation. Nuclear. Acids. Res. 49, 3217–3241. doi: 10.1093/nar/gkaa899

Chiu, Y. F., and Sugden, B. (2018). Plasmaid partitioning by human tumor viruses. J. Virol. 92, e02170–17.

Crawford, D. H. (2001). Biology and disease associations of Epstein-Barr virus. Phil. Trans. R. Soc. Lond. B. Biol. Sci. 356, 461–473.

Engels, N., Merchant, M., Papru, R., Chan, A. C., Longnecker, R., and Wienands, I. (2001a). Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLF-65 signaling module. J. Exp. Med. 194, 255–264. doi: 10.1084/jem.194.3.255

Engels, N., Wolfscheid, B., and Wienands, I. (2001b). Association of SLF-65/BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-alpha. Eur. J. Immunol. 31, 2126–2134. doi: 10.1002/1521-4141(20010731)71:6<2126::AID-immu2126>3.0.co;2-o

Fathallah, I., Parroche, P., Gruffat, H., Zannetti, C., Johansson, H., Yue, J., et al. (2010). EBV latent membrane protein 1 is a negative regulator of TLR9. J. Immunol. 185, 6439–6447. doi: 10.4049/jimmunol.0903459

Frederer, R., Linnstaedt, S. D., Bannert, H., Lips, H., Bencun, M., Cullen, B. R., et al. (2011). A viral microRNA cluster strongly potentiates the transforming functions of Epstein-Barr virus. EMBO. J. 30, 2356–2368. doi: 10.1038/embbriefs.2011.4930-4936.1992

Guasparri, I., Bubman, D., and Cesarman, E. E. B. V. (2008). LMP2A and BCL2 expression in tumor cells expressing Epstein-Barr virus. Proc. Natl. Acad. Sci. U. S. A. 105, 2091–2096. doi: 10.1073/pnas.0711941105

Hooykaas, M. J. G., van Gent, M., Poppe, J. A., Kruse, E., Boer, J. G. J., van Leenen, D., et al. (2017). EBV microRNA-BART14 suppresses type I IFN signaling. J. Immunol. 198, 4062–4073. doi: 10.4049/jimmunol.1700650

Huo, S., Luo, Y., Deng, R., Liu, X., Wang, J., Wang, L., et al. (2020). EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemotrauaction of Treg cells. J. Immunother. Cancer. 8:e01588. doi: 10.1136/jitc-2020-001588

Huyé, L. N., Ning, S., Kellhér, M., and Pagano, J. S. (2007). Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27, 2910–2918. doi: 10.1128/MCB.02256-06

International Agency for Research on Cancer [IARC] (1997). Epstein-Barr Virus; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC.

Iwaki, D., Zhou, L., Samanta, M., Matsutomo, M., Ebhara, T., Seya, T., et al. (2009). Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206, 2091–2099. doi: 10.1084/jem.200819761

Jangra, S., Bharti, A., Lui, W. Y., Chandhary, V., Botelho, M. G., Yuen, K. S., et al. (2021). Suppression of IAK-STAT signaling by Epstein-Barr virus tegument protein BGLF2 through recruitment of SHP1 phosphatase and promotion of STAT2 degradation. J. Virol. 95:e00721. doi: 10.1128/JVI.00721-21

Jochum, S., Moosmann, A., Lang, S., Hammerschmidt, W., and Zeidler, R. (2012a). The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS. Pathog. 8:e1002704. doi: 10.1371/journal. ppat.1002704

Jochum, S., Russ, R., Moosmann, A., Hammerschmidt, W., and Zeidler, R. (2012b). RNAs in Epstein-Barr virus control early steps of infection. Proc. Natl. Acad. Sci. U. S. A. 109, E1396–E1404. doi: 10.1073/pnas.1115906109

Jog, N. R., Chakravarty, E. F., Guthrie, J. M., and James, J. A. (2018). Epstein-Barr virus interleukin 10 suppresses anti-inflammatory phenotype in human monocytes. Front. Immunol. 9:2198. doi: 10.3389/fimmu.2018.0.2198

Kaiser, C., Laxx, G., Eick, D., Jochner, N., Bornkamm, G. W., and Kempkes, B. (1999). The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73, 4481–4488. doi: 10.1128/JVI.73.11.4481-4488.1999

Kalla, M., and Hammerschmidt, W. (2012). Human B cells on their route to latent infection—early but transient expression of lytic genes of Epstein-Barr virus. Eur. J. Cell Biol. 91, 65–69. doi: 10.1016/j.ejcb.2011.01.014

Kalla, M., Schmeinck, A., Bergbauer, M., Pich, D., and Hammerschmidt, W. (2010). AP-1 homolog ZBF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. U. S. A. 107, 850–855. doi: 10.1073/pnas.0907119107

Kanda, K., Becker, T., Amam, P., Wahlström, M., van Gabin, A., and Kallin, B. (1992). The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol. Cell. Biol. 12, 4930–4936. doi: 10.1128/MCB.12.11.4930-4936.1992

Kanda, K., Kempkes, B., Bornkamm, G. W., van Gabin, A., and Deckter, T. (1999). Epstein-Barr virus nucleic antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines. Biol. Chem. 380, 213–221. doi: 10.1515/BC.1999.029

Kempkes, B., and Ling, P. D. (2015). EBNA2 and Its coactivator EBNA-LP. Curr. Top. Microbiol. Immunol. 391, 35–59.

Kieser, A., and Sterz, K. R. (2015). The Latent Membrane Protein 1 (LMP1). Curr. Top. Microbiol. Immunol. 391, 119–199.

Kilger, E., Kaiser, C., Baumann, M., and Hammerschmidt, W. (1998). Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700–1709. doi: 10.1093/emboj/17.6.1700

Kumar, R., Whitehurst, C. B., and Pagano, J. S. (2014). The Rad6/18 ubiquitin ligase Fbxo10 is a negative regulator of the DNA damage response. Mol. Cell. Biol. 35, 461–470. doi: 10.1128/MCB.00383-14

Li, D., and Wu, M. (2021). Pattern recognition receptors in health and diseases. Signal. Transduct. Target Ther. 6:291.
Epstein-Barr virus-derived EBNA2 regulates STAT3 activation. Biochem. Cell Biol. 87, 6536–6546. doi: 10.1128/JVI.74.19.9115-9124.2000

Miyagi, S., Watanabe, T., Hara, Y., Arata, M., Uddin, K. M., Mantoku, K., et al. (2021). A sting inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis. Cancer Sci. 112, 5088–5099. doi: 10.1111/cas.15152

Mrozek-Gorska, P., Buschle, A., Pich, D., Schwarzmayer, T., Fechiner, R., Scialdone, A., et al. (2019). Epstein-Barr virus reprograms human B lymphocytes to carry out interferon signaling during productive infection. J. Virol. 87, 4069–4070. doi: 10.1128/JVI.02020-12

Samanta, M., Iwakiri, D., Kanda, T., Imaizumi, T., and Takada, K. (2006). EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J. 25, 4207–4214. doi: 10.1038/sj.emboj.7601314

Sato, E., Moosmann, A., Gromminger, S., Walz, N., Grundhoff, A., and Hammerschmidt, W. (2010). Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063. doi: 10.1371/journal.ppat.1001063

Sin, S. H., and Dittmer, D. P. (2012). Cytokine homologs of human gammaherpesviruses. J. Interferon Cytokine Res. 32, 53–59.

Skinner, C. M., Ivanov, N. S., Barr, A. S., Chen, Y., and Skalsky, R. L. (2017). An Epstein-Barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1. J. Virol. 91, e00530–17. doi: 10.1128/JVI.00530-17

Spender, L. C., Cornelius, G. H., Rowland, B., Kempske, B., and Farrell, P. J. (2001). Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75, 3537–3546. doi: 10.1128/JVI.75.8.3537-3546.2001

Stewart, S., Dawson, C. W., Takada, K., Curnow, J., Moody, C. A., Sziby, J. W., et al. (2004). Epstein-Barr virus-encoded LM2PA regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101, 15730–15735. doi: 10.1073/pnas.0402351101

Tagawa, T., Albanese, A., Moutet, M., Moomann, A., Mautner, J., Hessmayer, V., et al. (2016). Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J. Exp. Med. 213, 2065–2080. doi: 10.1084/jem.20160248

Valentine, R., Dawson, C. W., Hu, C., Shah, K. M., Owen, T. J., Date, K. L., et al. (2010). Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-κB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol. Cancer 9, 10.1186/1476-4598-9-1

van Gent, M., Graaf, H., van Gent, M., van Meter, M., and van den Broek, H. (2008). Epstein-Barr virus large tegument protein BFLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. PLoS Pathog. 10:e1003960. doi: 10.1371/journal.ppat.1003960

van Gent, M., Gram, A. M., Boer, J. G. J., Greidink, R. J., Lindenerberg, M. F. S., Lebbink, R., et al. (2015). Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion. J. Virol. 96, 858–865. doi: 10.1128/JVI.000021-15

van Gent, M., Gromminger, S., Walz, N., Grundhoff, A., and Hammerschmidt, W. (2010). Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063. doi: 10.1371/journal.ppat.1001063

Sin, S. H., and Dittmer, D. P. (2012). Cytokine homologs of human gammaherpesviruses. J. Interferon Cytokine Res. 32, 53–59.

Skinner, C. M., Ivanov, N. S., Barr, A. S., Chen, Y., and Skalsky, R. L. (2017). An Epstein-Barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1. J. Virol. 91, e00530–17. doi: 10.1128/JVI.00530-17

Spender, L. C., Cornelius, G. H., Rowland, B., Kempske, B., and Farrell, P. J. (2001). Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75, 3537–3546. doi: 10.1128/JVI.75.8.3537-3546.2001

Stewart, S., Dawson, C. W., Takada, K., Curnow, J., Moody, C. A., Sziby, J. W., et al. (2004). Epstein-Barr virus-encoded LM2PA regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101, 15730–15735. doi: 10.1073/pnas.0402351101

Tagawa, T., Albanese, A., Moutet, M., Moomann, A., Mautner, J., Hessmayer, V., et al. (2016). Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J. Exp. Med. 213, 2065–2080. doi: 10.1084/jem.20160248

Valentine, R., Dawson, C. W., Hu, C., Shah, K. M., Owen, T. J., Date, K. L., et al. (2010). Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-κB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol. Cancer 9, 10.1186/1476-4598-9-1

van Gent, M., Graaf, H., van Gent, M., van Meter, M., and van den Broek, H. (2008). Epstein-Barr virus large tegument protein BFLF1 contributes to innate immune evasion through interference with toll-like receptor signaling. PLoS Pathog. 10:e1003960. doi: 10.1371/journal.ppat.1003960

van Gent, M., Gram, A. M., Boer, J. G. J., Greidink, R. J., Lindenerberg, M. F. S., Lebbink, R., et al. (2015). Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion. J. Virol. 96, 858–865. doi: 10.1128/JVI.000021-15

van Gent, M., Gromminger, S., Walz, N., Grundhoff, A., and Hammerschmidt, W. (2010). Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063. doi: 10.1371/journal.ppat.1001063

Shah, K. M., Stewart, S. E., Wei, W., Woodman, C. B., O’Neil, J. D., Dawson, C. W., et al. (2009). The EBV-encoded latent membrane proteins. LM2PA and LM2PB, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene 28, 3903–3914. doi: 10.1038/onc.2009.249

Sin, S. H., and Dittmer, D. P. (2012). Cytokine homologs of human gammaherpesviruses. J. Interferon Cytokine Res. 32, 53–59.

Skinner, C. M., Ivanov, N. S., Barr, A. S., Chen, Y., and Skalsky, R. L. (2017). An Epstein-Barr virus microRNA blocks interleukin-1 (IL-1) signaling by targeting IL-1 receptor 1. J. Virol. 91, e00530–17. doi: 10.1128/JVI.00530-17

Spender, L. C., Cornelius, G. H., Rowland, B., Kempske, B., and Farrell, P. J. (2001). Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J. Virol. 75, 3537–3546. doi: 10.1128/JVI.75.8.3537-3546.2001

Stewart, S., Dawson, C. W., Takada, K., Curnow, J., Moody, C. A., Sziby, J. W., et al. (2004). Epstein-Barr virus-encoded LM2PA regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl. Acad. Sci. U. S. A. 101, 15730–15735. doi: 10.1073/pnas.0402351101
Vilmen, G., Glon, D., Siracusano, G., Lussignol, M., Shao, Z., Hernandez, E., et al. (2021). BHRF1, a BCL2 viral homolog, disturbs mitochondrial dynamics and stimulates mitophagy to dampen type I IFN induction. Autophagy 17, 1296–1315. doi: 10.1080/15548627.2020.1758416

Wang, D., Liebowitz, D., and Kieff, E. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831–840.

Wang, J. T., Doong, S. L., Teng, S. C., Lee, C. P., Tsai, C. H., and Chen, M. R. (2009). Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J. Virol. 83, 1856–1869. doi: 10.1128/JVI.01099-08

Wang, P., Deng, Y., Guo, Y., Xu, Z., Li, Y., Ou, X., et al. (2020). Epstein-Barr virus early protein BFRF1 suppresses IFN-β activity by inhibiting the activation of IRF3. Front. Immunol. 11:513383. doi: 10.3389/fimmu.2020.513383

Westhoff Smith, D., Chakravorty, A., Hayes, M., Hammerschmidt, W., and Sugden, B. (2021). The Epstein-Barr virus oncogene EBNA1 suppresses Natural Killer cell responses and apoptosis early after infection of peripheral B cells. mBio 12:e0224321. doi: 10.1128/mBio.02243-21

Whitehurst, C. B., Li, G., Montgomery, S. A., Montgomery, N. D., Su, L., and Pagano, J. S. (2015). Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice. mBio 6:e01574–15. doi: 10.1128/mBio.01574-15

Whitehurst, C. B., Vaziri, C., Shackelford, J., and Pagano, J. S. (2012). Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites. J. Virol. 86, 8097–8106. doi: 10.1128/JVI.00588-12

Wood, V. H., O’Neil, J. D., Wei, W., Stewart, S. E., Dawson, C. W., and Young, L. S. (2007). Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene 26, 4135–4147. doi: 10.1038/sj.onc.1210496

Wu, L., Fossum, E., Joo, C. H., Inn, K. S., Shin, Y. C., Johanssen, E., et al. (2009). Epstein-Barr virus LF2: an antagonist to type I interferon. J. Virol. 83, 1140–1146. doi: 10.1128/JVI.0602-08

Xing, J., Zhang, A., Zhang, H., Wang, J., Li, X. C., Zeng, M. S., et al. (2017). TRIM25 promotes DNA virus infections by inhibiting innate immune response. Nat. Commun. 8:4. doi: 10.1038/s41467-017-00101-w

Xu, C., Sun, L., Liu, W., and Duan, Z. (2018). Latent Membrane Protein 1 of Epstein-Barr virus promotes RIG-I degradation mediated by proteasome pathway. Front. Immunol. 9:1446. doi: 10.3389/fimmu.2018.01446

Yarchoo, R., and Uldrick, T. S. (2018). HIV-associated cancers and related diseases. N. Engl. J. Med. 378, 1029–1041.

Yin, Y., Manoury, B., and Faivre, R. (2003). Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301, 1371–1374.

Zeidler, R., Eissner, G., Meissner, P., Uebel, S., Tampe, R., Lazis, S., et al. (1997). Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 90, 2399–2397.

Zhang, J., Das, S. C., Kottakul, C., Pattnaik, A. K., and Zhang, L. (2004). The latent membrane protein 1 of Epstein-Barr virus establishes an antiviral state via induction of interferon-stimulated genes. J. Biol. Chem. 279, 46335–46342. doi: 10.1074/jbc.M403966200

Zhang, L., and Pagano, J. S. (2000). Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J. Virol. 74, 1061–1068.

Zhang, L., Hong, K., Zhang, J., and Pagano, J. S. (2004). Multiple signal transducers and activators of transcription are induced by EBV LMP-1. Virology 323, 141–152.

Zimber-Strobl, U., Kempkes, B., Marschall, G., Zeidler, R., Van Kooten, C., Banchereau, J., et al. (1996). Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15, 7070–7078.